作者
Alexandra J Lansky, Dean J Kereiakes, Andreas Baumbach, Stephan Windecker, Yasin Hussain, Cody Pietras, Ovidiu Dressler, Ozgu Issever, Michael Curtis, Barry Bertolet, James P Zidar, Pieter C Smits, Victor Alfonso Jiménez Díaz, Brent McLaurin, Sjoerd Hofma, Ángel Cequier, Nabil Dib, Edouard Benit, Anthony Mathur, David Brogno, Jacques Berland, Joanna Wykrzykowska, Guy Piegari, Salvatore Brugaletta, Shigeru Saito, Martin B Leon, PIONEER III Trial Investigators
发表日期
2021/6/1
期刊
Circulation
卷号
143
期号
22
页码范围
2143-2154
出版商
Lippincott Williams & Wilkins
简介
Background
Accelerated endothelial healing after targeted antiproliferative drug delivery may limit the long-term inflammatory response of drug-eluting stents (DESs). The novel Supreme DES is designed to synchronize early drug delivery within 4 to 6 weeks of implantation, leaving behind a prohealing permanent base layer. Whether the Supreme DES is safe and effective in the short term and can improve long-term clinical outcomes is not known.
Methods
In an international, 2:1 randomized, single-blind trial, we compared treatment with Supreme DES to durable polymer everolimus-eluting stents (DP-EES) in patients with acute and chronic coronary syndromes. The primary end point was target lesion failure—a composite of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization. The trial was designed to demonstrate noninferiority (margin of 3.58%) of the Supreme …
学术搜索中的文章
AJ Lansky, DJ Kereiakes, A Baumbach, S Windecker… - Circulation, 2021